Investigational drug · Phase 2
Orticumab
Also called: MLDL1278a, BI204
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "Orticumab"
First trial start
2025
Aug 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Orticumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Coronary Syndromes
- Coronary Arterial Disease (CAD)
- Inflammation
- Heart Disease
- Myocardial Infarct
- Atherosclerotic Coronary Vascular Disease
Approved drugs for the same conditions: Coronary artery disease and heart attack · Cardiovascular and metabolic · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Orticumab" as an intervention, largest first.
- Focused Orticumab Research for Treating Inflammation in Coronary ArteriesPivotal-lookingRecruiting
AbcentraIndustry
NCT06927739 · 240 participants (planned) · Start Aug 11, 2025 · Primary completion Feb 8, 2027
Drug: Orticumab; Placebo · For: Acute Coronary Syndromes; Coronary Arterial Disease (CAD); Inflammation and 3 more
Sites: Los Angeles, California; Torrance, California; Boca Raton, Florida · 41 sites in all
- A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk FactorsCompleted
AbcentraIndustry
NCT04776629 · 77 participants · Start Jun 30, 2021 · Primary completion Nov 11, 2022
Drug: Orticumab; Placebo · For: Psoriasis; Inflammation; Coronary Artery Disease and 1 more
Sites: Scottsdale, Arizona; Santa Monica, California; Tustin, California · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Oxidized LDL pathophysiology and potential as a therapeutic target in atherosclerosis.
Nilsson J, Villines TC, Libby P, et al. · Cardiovasc Res 2026
- Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy.
Farina CJ, Lu W, Nilsson J · Curr Opin Lipidol 2025
- Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial.
Farina CJ, Davidson MH, Shah PK, et al. · Cardiovasc Res 2024
- Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus.
Yao Mattisson I, Rattik S, Björkbacka H, et al. · Vascul Pharmacol 2021
- Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques.
Li S, Kievit P, Robertson AK, et al. · Mol Metab 2013
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.